Document is current

Article History

Received: 30 June 2023

Revised: 22 September 2023

Accepted: 24 September 2023

First Online: 21 October 2023

Declarations

:

: DO has received research support from Genentech, Genzyme, National Institutes of Health, National Multiple Sclerosis Society, Novartis, Patient-Centered Outcomes Research Institute, and Race to Erase MS Foundation; and has received consulting fees from Biogen, Genentech/Roche, Genzyme, Janssen, Merck, Novartis, and Pipeline Therapeutics. TC has received consulting fees from Genentech, Novartis, Sanofi Genzyme, Siemens; has received speaking fees from PRIME Education, LLC; and has received research support from BrainStorm Cell Therapeutics, Bristol Myers Squibb, Genentech/Roche, I-Mab Biopharma, National Institutes of Health, National Multiple Sclerosis Society, Novartis, Octave Bioscience, Sanofi Genzyme, Sumaira Foundation, Tiziana Life Sciences, and US Department of Defense. KR has received speaking, consulting, and advisory fees from Alexion Pharmaceuticals, Biogen, EMD Serono, Genentech, Genzyme, Horizon Therapeutics, Novartis, and TG Therapeutics; and has served as the principal investigator or co-investigator for grants to his institution from Alexion Pharmaceuticals, Biogen, EMD Serono, Genentech, Novartis, Sanofi Genzyme, and TG Therapeutics. AZO has received personal compensation for participation in scientific advisory boards, steering committees, and/or for speaking engagements from Alexion Pharmaceuticals, Banner Life Sciences, BD Biosciences, Biogen, Biologix Solutions, Bristol Myers Squibb, Celgene, EMD Serono, Genentech, GW Pharmaceuticals, Horizon Therapeutics, Jazz Pharmaceuticals, Novartis (local and global), Sandoz, Sanofi Genzyme, TG Therapeutics, and Viela Bio; has received consulting fee for serving as a scientific reviewer for the 2020 and 2022 Multiple Sclerosis Research Program (MSRP) for the Department of Defense Congressionally Directed Medical Research Programs (CDMRP); has received honoraria from Medscape, MJH Life Sciences, and WebMD; has served as a site principal investigator for studies funded (directly paid to Medical College of Wisconsin) by Atara Biotherapeutics, Biogen, Bristol Myers Squibb, Celgene, CorEvitas, EMD Serono, Genentech, GW Pharmaceuticals, Immunic Therapeutics, National Multiple Sclerosis Society/Patient-Centered Outcomes Research Institute, Novartis, Sanofi Genzyme, and TScan Therapeutics; and has received research funds from Central for Immunology, Clinical & Translational Science Institute (CTSI), National Institutes of Health, Neuroscience Research Center, and Research Affairs Committee.

: Not applicable.

: Not applicable.

: Not applicable.